Effect of orally administered Lactobacillus brevis HY7401 in a food allergy mouse model.
- 2013-11
- Journal of Microbiology and Biotechnology 23(11)
- Jeongmin Lee
- Jieun Bang
- H. Woo
- PubMed: 23985541
- DOI: 10.4014/JMB.1306.06047
Abstract
We had found that orally administered Lactobacillus species were effective immune modulators in ovalbumin (OVA)-sensitized mice. To validate these findings, we investigated the effects of orally administered Lactobacillus brevis HY7401 in OVA-T cell receptor transgenic mice. This strain showed a tendency to induce Th1 cytokines and inhibit Th2 cytokines. All assayed isotypes of OVA-specific antibody were effectively reduced. Systemic anaphylaxis was also relatively reduced with the probiotic administration. These results reveal that L. brevis HY7401 might be useful to promote anti-allergic processes through oral administration.
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Lactobacillus brevis | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis | Reduced Th2 Cytokine Levels | Beneficial | Moderate |
| Lactobacillus brevis HA-112 | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis HA-112 | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis LB01 | Reduced Allergic Responses | Beneficial | Moderate |
| Lactobacillus brevis LB01 | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis LB01 | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis LB01 | Reduced Th2 Cytokine Levels | Beneficial | Moderate |
| Lactobacillus brevis Lbr-35 | Induced Th1 Cytokines | Beneficial | Moderate |
| Lactobacillus brevis Lbr-35 | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis Lbr-35 | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis Lbr-35 | Reduced Th2 Cytokine Levels | Beneficial | Moderate |
| Lactobacillus brevis MAK11L82B | Reduced Allergic Responses | Beneficial | Moderate |
| Lactobacillus brevis MAK11L82B | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis MAK11L82B | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis MAK11L82B | Reduced Th2 Cytokine Levels | Beneficial | Moderate |
| Lactobacillus brevis SBC8803 | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis SBC8803 | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis SBC8803 | Reduced Th2 Cytokine Levels | Beneficial | Moderate |
| Lactobacillus brevis SD-5214 | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis SD-5214 | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis SD-5214 | Reduced Th2 Cytokine Levels | Beneficial | Moderate |
| Lactobacillus brevis UALbr-02 | Reduced OVA-Specific Antibodies | Beneficial | Large |
| Lactobacillus brevis UALbr-02 | Reduced Systemic Anaphylaxis | Beneficial | Moderate |
| Lactobacillus brevis VPro 18 | Increased Th1 Cytokine Production | Beneficial | Moderate |
| Lactobacillus brevis VPro 18 | Reduced Th2 Cytokine Production | Beneficial | Moderate |